#Israel #fertility care #Pulsenmore #Home Ultrasound #Omri

Pulsenmore's Expansion into Fertility Care

Pulsenmore Ltd., a healthcare technology company listed on NASDAQ and TASE, is making significant strides in the field of fertility care with the announcement of its latest innovation—Pulsenmore FC. This home ultrasound system has recently completed the CE European registration process, allowing it to be marketed across Europe for monitoring follicular development during IVF and fertility preservation treatments.

A Game Changer for Women's Health

With the increasing demand for assisted reproductive technology, where over 1.15 million IVF cycles were reported in Europe alone in the past year, Pulsenmore is stepping in to provide a solution that can enhance the patient experience. The traditional model often requires women to undergo frequent in-clinic ultrasound scans, which can be time-consuming and disruptive to their daily lives. By enabling these examinations to take place at home, Pulsenmore FC aims to alleviate some of this burden.

The system is equipped with a self-use ultrasound transducer and an application, providing remote guidance from healthcare professionals. This innovation allows women to manage a key aspect of their fertility treatment from the comfort of their own homes, thus reducing the frequency of clinic visits. This is particularly beneficial during intensive treatment cycles where monitoring is critical.

Proven Effectiveness

In a clinical study conducted at Rabin Medical Center, the efficacy of the Pulsenmore FC system was validated, showing a high correlation between home ultrasound scans and in-clinic evaluations. Patients and clinical staff reported high satisfaction levels, underscoring the system's reliability and the positive impact it has on patient care.

Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore, expressed enthusiasm about this milestone, stating, "We are transitioning from being a single-product company to a broader home ultrasound platform focusing on women's health. Our aim is to facilitate care that allows for portions of treatment to occur at home while healthcare professionals remain involved in the management of patient care."

Market Expansion and Future Potential

The CE registration signifies not just a triumph for Pulsenmore, but also highlights the company's commitment to expanding its portfolio within the women's health sector. Beyond its initial focus on prenatal monitoring, the company now has two products that cater to different stages of female health, emphasizing its innovative approach to personal healthcare.

Pulsenmore's journey doesn't end here. The company is leveraging its approval from the Ministry of Health in Israel and its recent partnership with Clalit Health Services to further establish its services. The registration under the European Medical Device Regulation (MDR) opens doors for collaborations with fertility centers and healthcare providers across Europe, expanding access to their groundbreaking technology.

With the rise of digital health solutions in today’s healthcare landscape, Pulsenmore is positioned to transform not only how fertility care is approached but also how women experience their treatment journeys. The promise of self-monitored home ultrasound technology is poised to redefine accessibility and convenience, allowing patients to stay in control of their healthcare while receiving the necessary support from medical professionals.

Overall, as the company continues to innovate within women's health, many will be looking forward to witnessing how Pulsenmore FC and future products evolve this essential field of care.